Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers

BACKGROUND: We present a radiomics-based model for predicting response to pembrolizumab in patients with advanced rare cancers. METHODS: The study included 57 patients with advanced rare cancers who were enrolled in our phase II clinical trial of pembrolizumab. Tumor response was evaluated using Res...

Full description

Saved in:
Bibliographic Details
Published in:J Immunother Cancer
Main Authors: Colen, Rivka R, Rolfo, Christian, Ak, Murat, Ayoub, Mira, Ahmed, Sara, Elshafeey, Nabil, Mamindla, Priyadarshini, Zinn, Pascal O, Ng, Chaan, Vikram, Raghu, Bakas, Spyridon, Peterson, Christine B, Rodon Ahnert, Jordi, Subbiah, Vivek, Karp, Daniel D, Stephen, Bettzy, Hajjar, Joud, Naing, Aung
Format: Artigo
Language:Inglês
Published: BMJ Publishing Group 2021
Subjects:
Clinical/Translational Cancer Immunotherapy
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8051405/
https://ncbi.nlm.nih.gov/pubmed/33849924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001752
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items